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Abstract  
The microbiota can play important roles in the development of human immunity and the 
establishment of immune homeostasis. Lifestyle factors including diet, hygiene, and 
exposure to viruses or bacteria, and medical interventions with antibiotics or anti-ulcer 
medications, regulate phylogenetic variability and the quality of cross-talk between innate 
and adaptive immune cells via mucosal and skin epithelia. More recently, microbiota and 
their composition have been linked to protective effects for health. Imbalance, however, has 
been linked to immune-related diseases such as allergy and cancer, characterized by 
impaired, or exaggerated immune tolerance, respectively. In this AllergoOncology position 
paper, we focus on the increasing evidence defining the microbiota composition as a key 
determinant of immunity and immune tolerance, linked to the risk for development of allergic 
and malignant diseases. We discuss novel insights into the role of microbiota in disease and 
patient responses to treatments in cancer and in allergy. These may highlight opportunities 
to improve patient outcomes with medical interventions supported through a restored 
microbiome. 
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1. Introduction 
 
Why studying microbiota is important for the field of AllergoOncology 
The collective genome of all microorganisms living in and on the surfaces of the human body 
is defined as the microbiome and contains 150 times more genes than the 23,000 protein-
coding genes of human origin (Table 1). The human microbiome project (1) has contributed 
to understanding of the composition, function and diversity of the human microbiota, i.e. all 
microorganisms populating the inner and outer surfaces of the human body, including 
viruses, fungi, protozoa, archaea, and bacteria (Table 2).   
The human microbiota show remarkable variability and have a mutualistic relationship with 
the human host. The microbiome profoundly affects the epithelium and the mucosal immune 
system and vice versa. There is growing evidence that microbiota play a paramount role in 
the control of immune mediated diseases such as allergy and cancer, the two 
complementary diseases in the frame of AllergoOncology (2). 
 
Hygiene hypothesis in allergy: From epidemiology to mechanisms 
The allergy epidemics correlate with improved hygiene practices associated with urban 
lifestyles (Suppl. Table 1). Milestone studies revealed that this epidemic can be counter-
regulated in part by exposure to a traditional farming environment. The cornerstones of the 
allergy protective farm effect are: i) farm activities during pregnancy, ii) early life farm 
exposure, and iii) raw milk consumption, but farms are also protective against viral 
infections. Protection depends on the farm dust levels in an area, and on the type of farming. 
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To give an example, children from Amish traditional pre-industrial farming communities were 
less prone to allergy development than Hutterites who use modern industrial farming 
methods. Amish farm dust initiated innate immune pathways associated with protection from 
allergy development in a mouse model. Additionally, rich microbial exposure by cohabitation 
with wild mice improves the immune response in laboratory mice. In line with this, dog 
keeping is reported to protect children from asthma. Also helminth infections can support the 
establishment of protective microbiota (for summary and references see Suppl. Table 1). 
Molecular mechanisms are increasingly understood. Viral antigens due to molecular mimicry 
counteract specific allergen sensitization and induce specific T effector memory responses. 
Exposure to N-Glycolylneuraminic acid (Neu5Gc), a sialic acid compound in farm dust, 
induces regulatory pathways. Endotoxin exposure of bronchial epithelial cells counteracts 
allergen-induced Th2 responses. Prenatal farm exposure supports Treg and Th17 cell 
differentiation. The protective immunity associated with the consumption of raw milk induces 
FOXP3 demethylation and T regulatory cells. Exposure of bronchial epithelia to farm dust, 
for instance containing CpG-DNA, or of gut epithelia to farm milk enhances epithelial barrier 
integrity, resulting in protective innate immunity to allergens and viruses (Suppl. Table 1). 
In accordance, immature gut microbial composition at age 1-year was positively associated 
with asthma risk at 5-years in children with asthmatic mothers (3). There were inverse 
associations with relative abundances of genera Faecalibacterium, Bifidobacterium, 
Roseburia, Alistipes, Lachnospiraceae incertae sedis, Ruminococcus, and Dialister, and a 
positive association with Veillonella. Inverse associations of relative abundances of genera 
Lachnospira, Veillonella, Faecalibacterium, and Rothia at age 3-months and atopy and 
wheeze at age 1-year were observed in another study (4), as was amelioration of lung 
inflammation in adult offspring of germ-free mice inoculated with these taxa. The group at 
highest risk for multisensitized atopy (2-years) and asthma (4-years) was characterized by 
lower abundance of gut bacteria Bifidobacterium, Akkermansia, Faecalibacterium, and 
Lactobacillus and higher abundance of fungi Candida and Rhodotorula at 1-11 months (5). 
Decreased gut microbiome diversity was correlated with CD4+ T cell decline in immune-
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deficient patients (6). Increasing use of antibiotics has been linked with dysbiosis and 
enhanced prevalence of allergies and asthma (7). Also, the pharmacologic impairment of 
gastric digestion is associated with gut dysbiosis and has been correlated with allergy in 
mice and humans (8, 9). However, study results of probiotic supplementation in childhood 
asthma or wheeze are inconclusive (10). 
 
Hygiene hypothesis in oncology: From epidemiology to mechanisms 
Increased incidence of certain cancers in Westernized countries (11) may be associated with 
under-exposure to certain microbial species, modern lifestyle, and consumption of sterilized 
food (12). Higher socioeconomic status is associated with increased incidence of Hodgkin 
lymphoma (13), while daycare attendance and higher number of childhood infections are 
linked with lower risk of acute lymphoblastic leukemia (14) and adult chronic lymphoid 
leukemia (15). Increased cancer risk is observed in patients with autoimmune diseases and 
chronic allergic disorders (16). Mice with rapid melanoma growth and poor 
immunosurveillance, exhibited relatively low levels of Bifidobacterium species which when 
restored by oral feeding and co-housing, resulted in enhanced tumour antigen presentation 
and reduced malignant growth (17).  
Epidemiological studies have also examined specific bacteria, viruses, periodontal disease, 
and circulating antibodies to selected pathogens in relation to cancer risk (18). Carriage of 
Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans in pre-diagnostic 
oral wash samples was positively associated with pancreatic cancer risk and Fusobacteria 
and its genus Leptotrichia were inversely associated (19). Tannerella forsythia was positively 
associated with esophageal adenocarcinoma and Porphyromonas gingivalis with squamous 
cell carcinoma (20). Greater abundance of genera Corynebacterium and Kingella were 
inversely associated with head and neck squamous cell cancer (21).  
An omnivore, but not a vegetarian, diet promotes butyrate-producing Lachnospiraceae 
(Firmicutes/Clostridiales). Bifidobacterium spp (Actinobacteria/ Bifidobacteriales/ 
Bifidobacteriaceae) are strongly stimulated by dietary intake of oligosaccharides as present 
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in milk, while Erysipelotrichi (Firmicutes/Erysipelotrichales/Erysiopelotrichaceae) are 
stimulated by high fat, Western diets (22). A prudent diet (rich in whole grains and fiber) was 
associated with a lower risk of Fusobacterium nucleatum-positive colorectal cancer 
incidence (23). African Americans fed a high-fibre, low-fat diet and rural Africans a high-fat, 
low-fibre diet, demonstrated reciprocal changes in colonic mucosal inflammation and 
biomarkers of cancer risk and in colonic microbiota and metabolome including in 
saccharolytic fermentation and butyrogenesis, and secondary bile acid synthesis (24). 
It has also been postulated that the use of antibiotics may support cancer progression 
through subversion of immunosurveillance. In a transgenic mouse model of spontaneous 
mammary carcinoma development, treatment with metronidazole and ciprofloxacin resulted 
in accelerated development of these tumours (25). Repeated antibiotic use may also 
increase risk of certain human malignancies (26). 
 
2. Metabolites critically shape the microbiome  
 
Dietary micronutrients  
Micronutrients being essential food for microbes substantially influence microbiota 
composition. Most bacteria require iron and have evolved multiple strategies for 
sequestration including the production of hemophores and low molecular iron chelators 
named siderophores. Iron supplementation promotes the establishment of bacteria relying 
on this metal (Table 3). In atopy a poor iron status is associated with allergy, whereas an 
improved status abrogates or seems to prevent the onset of allergy. In cancer, iron 
contributes to tumor growth with high serum iron increasing the risk of several cancers 
(Table 4) (27).  
Vitamin A and D (Tables 3 and 4) are important for mucosal immunity (28). Retinol 
supplementation does not change the risk of allergy (29) or cancer (30), though increased 
serum retinol levels are associated with prostate cancer (31). Vitamin D supplementation 
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slightly decreases respiratory infections and the incidence of asthma in off-spring (32), 
prevents hematologic malignancies in elderly women and advanced colorectal adenomas 
(33), but seem not to impact allergy risk (34). Vitamin D supplementation decreases the 
abundance of Bifidobacterium and Coprococcus (35). 
Serum folate levels are associated with serum IgE (36), high plasma folate is associated with 
decreased risk of wheezing (37), and folic acid supplementation has been linked with an 
increased risk for lung cancer (38). Folate can be produced by most Bacteroidetes, 
Fusobacteria and Proteobacteria, but rarely from Actinobacteria and Firmicutes (39). In 
summary, dietary micronutrients shape the microbiome which contributes products essential 
for an effective immune defence.  
 
Non-digestible Oligosaccharides  
Non-digestible Oligosaccharides (NDO) are potential substrates for bacterial metabolism in 
the colon and a declining microbial diversity in the gut is implicated in the rising incidence of 
allergic disorders in early life (40). Manipulation of the gut microbiota with NDO from natural 
sources or supplemented galacto-oligosaccharides (GOS), lactose and fructo-
oligosaccharides (FOS) holds great promise for the treatment of inflammatory and allergic 
diseases (Table 4). NDO feeding reduced the development of atopic dermatitis (AD) in 
infants at risk of allergy which was associated with increased Bifidobacterium and 
Lactobacilli (41, 42), re-balancing the immune response from a predominant Th2-type 
allergic profile at birth to a more Th1-type and regulatory T cell profile. NDO protect against 
allergic manifestations in experimental models of food allergy and allergic asthma (43, 44), 
and reshape the gut microbiota with increased levels of short chain fatty acids (SCFAs) (45). 
Less is known concerning the anti-cancer effects of NDO (46). Experimental models show 
encouraging effects of GOS, FOS, agaro-oligosaccharides (47) and butyrate (46) in 
influencing microbiota diversity (e.g. increased Fusobacterium) and the prevention and 
progression of colorectal cancer (48). NDO showed potential in the protection against the 
development of cancer in healthy subjects (49). Since Western diets are typically low on 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
NDO, increasing the intake of NDO may benefit human health via an improved microbiome 
and/or via direct effects on the immune system.    
 
Microbiota metabolites  
Dairy products such as yogurt and butter contain short chain fatty acids (SCFAs), while 
SCFAs are also produced by intestinal bacteria following their fermentation of fibers present 
in vegetables and fruits.(50) The major SCFAs are acetate, propionate and butyrate. SCFAs 
are an important energy source for intestinal epithelial cells and regulate the assembly and 
organization of epithelial tight junctions. Abnormalities in the production of these metabolites 
(due to dietary factors and/or microbial dysbiosis) might play a role in the pathogenesis of 
type-2 diabetes, obesity, inflammatory bowel disease, colorectal cancer and allergies (51, 
52). Butyrate influences the activity of histone deacetylases (HDAC), responsible for 
decreasing dendritic cell IL-12 and IL-6 secretion, and allows dendritic cells to promote 
Tregs. Propionate can also contribute to the induction of T cell Foxp3 expression by dendritic 
cells, while acetate does not have this activity, possibly due to the lack of HDAC activity (53). 
G-Protein coupled receptors GPR109a and GPR43 have been described to contribute to 
these effects, while GPR43 expression on colonic inducible Treg cells is associated with 
their expansion and IL-10 secretion (54, 55). 
 
3.  Microbiota regulating cellular players in Innate and adaptive responses  
 
Cells of the epithelial barrier  
Epithelial cells have a very close interaction with compartment-specific microbiota (Figure 
1). These cells are able to sense conserved microbial associated molecular patterns by 
innate pattern recognition receptors (PRR) such as TLRs and Nod-like receptors. These 
interactions can control epithelial cell proliferation and barrier function (56). Not only direct 
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interaction, but also microbiota derived metabolites such as SCFAs and bacterial quorum 
sensing (QS) can have an impact on epithelial cells. In the intestine, SCFAs stimulate the 
inflammasome pathway via binding to GPRs on the surface of epithelial cells. Associated 
with enhanced epithelial IL-18 secretion, barrier integrity is enhanced and epithelial cells 
secrete more antimicrobial peptides (57, 58). Both, SCFA and QS signals have 
immunomodulatory potential by stimulating survival pathways and contributing to intestinal 
homeostasis (59-61). Thus, microbiota and metabolites have a paramount influence on 
epithelial cell function. 
 
Dendritic cells  
As professional antigen presenting cells (APC), dendritic cells (DC) are in contact with both 
invading pathogens and commensal microbiota and maintain the balance between 
inflammatory and tolerogenic immune responses. Human monocyte-derived dendritic cells 
(moDCs), when matured in the presence of the SCFA butyrate, increase IL-10, but decrease 
IL-6 and IL-12 expression (62). Similarly, treatment of mice with the SCFA propionate 
generate new bone marrow DC precursors with high phagocytic capacity but an impaired 
ability to promote T helper type 2 (Th2) responses in the lung. This effect is dependent on G 
protein–coupled receptor 41 (GPR41, also called free fatty acid receptor 3 or FFAR3), but 
not GPR43 (also called free fatty acid receptor 2 or FFAR2) (55). DCs can also exert roles in 
adoptive T cell therapy (ACT) in cancer, and the composition of the gut microbiome or 
treatment with antibiotics could lead to an increase in CD8α+ DCs, and consequent IL-12 
release that sustains the anti-tumor ACT (63). 
 
Macrophages  
The microbiota and its metabolites such as SCFAs strongly influence myelopoiesis and the 
tissue-resident macrophages. In the intestine, microbial SCFA butyrate activates its 
endogenous receptor GPR109a promoting anti-inflammatory properties in colonic 
macrophages that induce differentiation of Treg cells and IL-10-producing T cells. Such 
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responses may be beneficial in food tolerance, but perhaps not in cancer. Moreover, 
butyrate exerts an anti-inflammatory effect on lamina propria macrophages by inhibition of 
IL-6, IL-12 and NO via inhibition of HDACs (64). Noteworthy, this mechanism did not affect 
primary LPS response genes such as Tnf and Ccl2. Microbiota can also affect macrophage 
phenotype and response if they are not in contact with the innate immune system. In the 
CNS of germ-free mice, macrophages (microglia) display an altered phenotype. In the lungs 
of mice treated with antibiotics, macrophages are polarized towards a M2 pro-allergic 
phenotype by prostaglandin E2 (PGE2) enhanced by commensal fungi (65). 
 
Mast cells  
Mast cells (MC) are crucial effector cells in allergy and other inflammatory diseases (66). 
They also play important roles in regulating the microenvironment of various tumors (66). 
There is increasing evidence that MC function can be modulated by commensal, symbiotic 
and pathogenic microorganisms (67). Microorganisms may influence MC activation via direct 
interaction or via secreted metabolites. For example, co-culture with Lactobacillus 
rhamnosus downregulates gene expression for the high affinity IgE receptor and histamine 
H4 receptor in human MC, while increasing IL-8, IL-10, CCL2 and TNFα (67). Stabilization of 
MC by L. rhamnosus is possibly induced indirectly via targeting the KCa3.1 channel (68). 
Some Lactobacillus strains, such as L. paracasei, inhibited IgE-mediated activation of 
murine MC with a possible involvement of TLR2. Inhibition by L. casei is cell contact-
dependent, but TLR- or Nod1/2-independent (67). Inhibition of MC activation by microbiota-
derived metabolites such as SCFA may be mediated via the surface receptors GPR41, 
GPR43 and GPR109A (69, 70) nuclear receptor family peroxisome proliferator-activated 
receptors (PPAR) or direct inhibition of histone deacetylase activity (71). The bioactive milk 
peptide glycomacropeptide (GMP) increased intestinal Lactobacillus and Bifidobacterium 
levels in rats and decreased allergen-induced MC activation (72). 
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Eosinophils  
Eosinophils are granulocytic leukocytes that exert important functions in protective immune 
responses against helminths and other pathogens (73). They also serve as key effector cells 
in allergies and other inflammatory diseases. Recent studies demonstrated that eosinophils 
crucially participate in maintaining the specific tissue resident microbiome (74). Conversely, 
functions of eosinophils are regulated by pathogenic as well as probiotic microorganisms; 
e.g. human eosinophils were found to ingest Clostridium difficile, which subsequently 
stimulated the release of eosinophil-derived neurotoxin (75). In contrast, ingestion of the 
probiotic strain Bifidobacterium bifidum resulted only in a minor neurotoxin release (75). 
Comparably, mouse eosinophils were found to take up the probiotic Lactobacillus reuteri 
(76). Using various mouse models of asthma and AD, probiotics like Lactobacillus 
fermentum and Lactobacillus rhamnosus were found to improve allergic inflammation 
associated with decreased eosinophil infiltration, although a direct effect of probiotic bacterial 
strains on eosinophils was not demonstrated in these studies (77, 78). 
 
ILCs  
Innate lymphoid cells (ILCs) develop normally in the absence of the microbiota, however, 
signals from commensal microorganisms influence the maturation and acquisition of the 
tissue-specific functions of ILCs. ILC3 cells maintain tolerance to commensal-specific T cell 
responses and their depletion and subsequent abrogation of IL-22 production, results in loss 
of intestinal bacteria (65) Moreover, ILC3s release GM-CSF and induce tolerance when 
intestinal macrophages release IL-1β in response to microbial sensing. A recent study 
demonstrates that TNF-β production by ILC3s is crucial for the production of IgA and for 
microbiota homeostasis in the intestine. Another ILC subtype, ILC2s, are activated by IL-25 
produced in a microbiota-dependent manner by epithelial tuft cells. Deletion of the ILC1-
lineage transcription factor T-bet in the innate immune system results in ILC-dependent and 
Helicobacter typhlonius-driven inflammation of the intestine, connected to cancer initiation 
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and promotion (65). Taken together, the microbiota and their metabolites shape the 
spectrum of different immunoregulatory ILCs and modulate their ability to prevent tumour 
immune evasion or allergic responses. 
 
Tregs  
Tregs are potent immune regulating cells that play a central role in controlling immune 
responses. Tregs can support the reduction of allergic diseases, and, on the other hand, the 
progression of cancer (79). Multiple mechanisms are employed by Treg cells and include 
production of inhibitory cytokines (IL-10, TGF-β and IL-35), cytolysis of effector T cells and 
APCs (via granzymes A and B), direct inhibition of DCs (e.g. via PD-1 and CTLA4) and 
metabolic disruption of effector cells (CD25, cAMP, adenosine, CD39, and CD73) (80). 
Germ-free mice do not fully develop Tregs, similarly to mice treated with antibiotics or mice 
lacking Toll-like receptors (TLRs). However, not all bacterial strains are equally effective in 
inducing Tregs. Bifidobacterium longum 35624, Clostridia and Bacterioides fragilis have 
been shown to induce intestinal Treg cells, while other bacterial strains do not induce Tregs 
(81, 82). Pattern-recognition receptor activation on DCs seems to be an important 
mechanism by which intestinal microbes may promote Treg cell differentiation (83). 
 
B cells and B regs  
B cells are known to promote allergy through antigen presentation and class-switching to 
IgE, whereas under certain conditions, tumour-infiltrating B cells can be associated with 
improved patient survival in cancer (79, 84). In contrast, Breg-associated immune tolerance 
can lead to control of allergy or tumour progression in cancer (79). 
The microbiome may have a role in mediating these multifaceted and opposing B cell effects 
in allergy and cancer. Microbiota regulate activation and differentiation of B cells (85). Gut 
microbiota antigens directly trigger B cell activation by binding BCRs, and microbial products 
activate TLR-expressing B cells, increasing B cell survival, antigen presentation and 
antibody production (86). Microbiota also mediate the release of epithelial cell and 
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eosinophil-derived cytokines/chemokines that activate and recruit B cells, and may promote 
T follicular helper cell-mediated differentiation of plasma cells (85). Conversely, the gut 
microbiome reportedly induces DCs to produce cytokines, such as IL-1β and IL-6, which 
promote B cell differentiation to Bregs (87).  
These findings point to a functional cross-talk between humoral immunity and the 
microbiome.  
 
4.  Molecular crosstalk of microbiota with innate and specific immune 
defence  
 
Redox regulation in allergy and cancer  
Recent reports demonstrated that certain microbes can stimulate intracellular signaling, 
involving PTEN, MAPK and PTP via the generation of reactive oxygen species (ROS) in 
epithelia, when harboring regulatory redox-sensitive thiolates (88). Commensal bacteria alter 
the epithelial redox environment by production of oxygen radicals, cause epithelial cell DNA 
damage and may harbor carcinogenic properties, for example in colon carcinoma 
development (89). Furthermore, allergic asthma is associated with an increase in 
endogenous ROS formation, leading to oxidative stress–induced damage to the respiratory 
system and weakened antioxidant defences. These may result in abnormal physiologic 
function of DNA, proteins, and lipids that can augment bronchial hyperresponsiveness and 
inflammation (90). 
Overall, the microbiome is implicated in redox regulating pathways, which are relevant for 
both chronic inflammation and cancer. 
Lipocalins  
Human lipocalins, such as tear lipocalin 1 and lipocalin 2 present in the nasal mucosa, can 
interfere with bacterial iron sequestration (27), and may directly modulate site-specific 
microbial composition. The immunomodulatory and apoptosis-regulating properties of LCN2 
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have been linked to its ability to shuttle iron (91). In line with the hygiene hypothesis, the 
limited “microbial exposure” of allergic individuals may also result in deficiencies of the 
immune regulatory machinery and this can lead to hyper-reactive responses (92). 
Interestingly, nearly all major mammalian allergens belong to the lipocalin family (93), and 
are similarly able to bind to bacterial and plant-derived iron chelators, pointing to a potential 
role for interference of LCN2 function. In several cancer types and in line with a perturbed 
iron regulation, LCN2 plays an important role in oncogenesis and cancer progression and 
may serve as a disease biomarker (94). 
 
Antibodies  
Microbiota associated antigens can induce IgA-producing plasma cells in the gut; CD40-
ligand and IL-21 from T follicular helper cells, APRIL and BAFF from DCs, induce Activation-
Induced Cytidine Deaminase (AID) expression by B cells, promoting IgA class switch 
recombination. As the composition of the microbiota changes, so do the IgA repertoires (95).  
In a recent mouse study, IL-33 deficient mice, with significantly-lower levels of intestinal IgA 
and colon-residing IgA+ B cells, had increased DNA damage-induced tumours; observations 
that were ameliorated upon microbiome restoration by co-housing deficient animals with 
wildtype mice (96). In humans, altered gut microbiota diversity and low total IgA levels may 
be associated with development of allergies and asthma (97), and IgA-deficient individuals 
have a moderately increased risk of cancer, with higher risks in gastrointestinal cancer (98). 
This disease risk may be a result of impaired mucosal barrier function. However, the 
associations between microbiota-driven antibody production with allergies and cancer are 
not yet sufficiently understood.   
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5. Translational implications of microbiota  
 
Oncoimmunology and allergy  
Specific microbes and the microbiota in general can be considered as important drivers of 
immunomodulation and can contribute to establishing immune tolerance, with differential 
impact on the many diverse immune-mediated diseases. Due to the close interaction and the 
bidirectional influence of intestinal microbiota on the mucosal immune system, the gut can 
be considered as an essential site of immune cross-talk in the human host. When it comes 
to allergy or cancer, however, regulation of tolerance has an opposing impact on disease 
development and treatment (79). 
In cancer the impact of microbiota was for a long time primarily considered in the context of 
dysbiosis, increased epithelial translocation and carcinogenic effector mechanisms (99). 
However, in recent years, emerging knowledge points to the role of microbiota, especially in 
the gut, in anti-cancer immune mechanisms (100). This is due to studies describing a 
reduced anti-cancer efficacy of chemotherapeutics such as cyclophosphamide and platinum 
salts in germ-free and antibiotic-treated mice. Moreover, the redox equilibrium of myeloid 
cells contained in the tumor microenvironment is influenced by intestinal microbiota and due 
to the importance of the gut in immune fitness, intestinal microbes are essential for the 
availability of immunomodulators.  
In cancer immunotherapy, major advances have been made in the past years to understand 
the contribution of microbiota composition to successful treatment. Studies are now starting 
to evaluate the role of the gut microbiome in anti-PD-1 immunotherapy (101, 102), including 
the first clinical study focusing on PD-1 checkpoint inhibitor response in metastatic 
melanoma. In a recent ground-breaking study, the authors were able to demonstrate a 
correlation between response to PD-1 checkpoint inhibitor treatment and diversity of 
microbial strains in the intestine. Moreover, high abundance of Faecalibacterium and low 
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abundance of Bacteroidales was associated with good prognosis and longer progression-
free survival after checkpoint inhibitor treatment (101). Moreover, toxicity-related side effects 
and a dysfunctional intestinal epithelial barrier seem to be attenuated by a beneficial 
microbiota composition, potentially acting not only via modulation of the host immune 
response but also via modulation of cancer metabolism (103, 104). 
Even though immunotherapy has been the treatment of choice for allergic diseases for more 
than a century, it seems that the cancer field is more advanced than allergy research with 
regards to evaluating the role of microbiota. There is a growing number of studies proving 
the major immunomodulating effects of intestinal microbiota and dietary supplementation 
with probiotic strains, as well as growing evidence demonstrating the role of intestinal 
microbial colonization in prevention and onset of allergic disease (9, 105). However, only a 
limited number of studies have so far evaluated the influence of beneficial bacterial strains in 
the context of successful allergen specific immunotherapy (AIT). Beneficial 
immunomodulatory and clinical effects of probiotic supplementation was observed when 
using different probiotic strains such as L. rhamnosus in a randomized clinical trial of peanut 
oral immunotherapy or in grass-pollen sublingual immunotherapy (SLIT) or by combining 
SCIT with Clostridium butyricum supplementation (106-108). Thus, major research efforts 
will be essential in the future to close this current knowledge gap and to ensure optimized 
AIT formulations for efficient treatment of allergic patients. 
 
Microbial translocation in cancer and allergy  
Under certain conditions, the normal gut epithelial barrier can become leaky, permitting the 
passage of microbes and microbial molecules into the systemic circulation, known as 
microbial translocation. Microbial products, especially cell walls of gram-negative bacteria 
(lipopolysaccharide [LPS] or endotoxin) are powerful stimulators of innate immunity and of B 
cell activation, resulting in inflammation that can lead to disease states, and even septic 
shock if present in very high doses (109). Microbial translocation can be assessed by 
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measuring the immune molecules stimulated by LPS, including soluble CD14 (sCD14), LPS-
binding protein (LBP), and antibodies recognizing the core LPS antigen (Endocab) (109).  
Gut barrier permeability is well-established in the setting of HIV infection. Two different 
prospective cohort studies reported that immune markers reflecting microbial translocation 
are associated with an elevated risk of AIDS-related non-Hodgkin lymphoma (NHL) (110, 
111), presumably due to increased B cell activation resulting from the triggered innate 
inflammation signals. Both studies found that sCD14, measured years prior to diagnosis, 
was associated with a 2-4-fold increase in NHL risk, but the findings were inconsistent with 
respect to the other measures. Besides implications of microbial translocation in food allergy 
and asthma, it also strongly influences AD (112). A randomized trial among adult AD 
patients, given either selected probiotics or placebo, resulted in clinical improvement, 
decreased T-helper type 2 (Th2) immune activation and reduced plasma LPS as a measure 
of microbial translocation (112). Thus, microbial translocation may play a role in the etiology 
of both AIDS-related lymphoma and AD. It may therefore be possible to decrease risk by 
reducing microbial translocation through the selective use of probiotics. 
 
Outlook: microbiota engineering  
The beneficial effect of a balanced microbiota on human health can be restored or 
potentiated by external/medical intervention. There are three main routes to microbiota 
engineering (Figure 2). Firstly, in pathological conditions commensal bacteria could be 
administered to move towards a species composition more representative of a healthy 
microbiota. Examples are fecal transplantation and vaginal swab, but other types of more 
specific interventions are being studied. Secondly, bacterial biosynthetic pathways could be 
engineered for de novo or enhanced production of compounds that can promote healthier 
mucosal environments and homeostasis. Thirdly, selected commensal bacterial strains 
(especially lactic acid bacteria) could be engineered for the live delivery of recombinant 
therapeutic proteins either to prevent or to combat disease (113, 114). To this end, live 
recombinant protein delivery could occur via secretion, membrane-anchorage or intracellular 
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load. Engineering biosynthetic pathways or exogenous recombinant protein production 
implies the genetic modification of commensal bacteria, therefore sophisticated strategies to 
control their survival in the host and in the local environment are being devised (115). 
Cancer and allergy are widely the focus of many of these efforts (Figure 2), with a number of 
studies showing how microbiota composition and its engineering may ameliorate or support 
the appropriate immune response to contribute to clinical benefits for each condition (116). 
 
6. Conclusion  
The biodiversity hypothesis is a cornerstone in the understanding of the allergy epidemics. 
Subsequently, the era of microbiota research has opened up novel perspectives on allergy 
pathogenesis (117), but also on cancer due to the immunomodulatory properties of the 
mutualistic microbes. The impact of the microbiota can be direct or indirect by cellular cross-
talk with and among innate or specific immune cells, by translocation of microbiota via 
epithelia into tissues, or by the exchange of molecules which may stimulate inflammatory or 
regulatory cells. The subsequent result can be inflammation or reconstitution, with opposing 
consequences in allergy and cancer. Importantly, the composition of the human microbiota 
can be disturbed by environmental factors, composition of the diet, and especially by 
medical interventions such as antibiotics and anti-ulcer medications. Phylogenetic variability 
and stable composition of microbiota seem to be determined in early life, defining this as a 
critical period for establishing health and homeostasis. However, it also offers a potential 
window of opportunity for interventions aiming at the establishment of a healthy microbiota to 
support long-term human health.   
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Abbrevations  
APRIL  A proliferation-inducing ligand 
AD   atopic dermatitis 
BAFF B-cell activating factor 
ACT   adoptive T cell therapy 
APC  antigen presenting cells 
CNS  central nervous system 
CCL2 gene of C-C motif chemokine 2 
CTLA4 Cytotoxic T-Lymphocyte Associated Protein 4 
DC  Dendritic cells 
FFAR3 free fatty acid receptor 3  
FOS  fructo-oligosaccharides 
HDAC  histone deacetylases 
GOS  galacto-oligosaccharides 
GMP  glycomacropeptide 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
IL  interleukin 
ILC  Innate lymphoid cells  
LPS Lipopolysaccharide 
LBP   LPS-binding protein 
NDO Non-digestible Oligosaccharides 
Nod-like nucleotide-binding oligomerization domain-like 
SCFAs   short chain fatty acids 
HDAC   histone deacetylases 
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PD-1 Programmed cell death protein 1 
PPAR  peroxisome proliferator-activated receptors 
PRR  pattern recognition receptors 
Th2  T-helper type 2 
Treg T-regulatory cell 
GPR  G-Protein coupled receptor  
HIV human immunodeficiency virus 
MAPK  Mitogen-activated protein kinase 1 
NHL   non-Hodgkin lymphoma 
PTEN Phosphatidylinositol 3,4,5-trisphosphate 
PTP protein tyrosine phosphatase 
QS   quorum sensing 
ROS   reactive oxygen species 
sCD14  soluble CD14 
TLR toll like receptor 
TNFα tumor necrosis factor 
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Figure legends 
Figure 1. Interaction of microbiota with immune cells in health and disease. (A) 
Bidirectional interaction between gut microbiome and players of the immune system. Cells 
from the epithelial barrier (epithelial cells and dendritic cells) sense the microbiome through 
the expression of a large panel of receptors. In health, such interactions are essential for the 
maintenance of the local microbial homeostasis and the integrity of epithelial barriers. This 
mechanism involves a variety of regulatory immune cells resident in the gut mucosa as well 
as molecules secreted by the epithelial layer. (B) Human eosinophils were shown to secrete, 
among others, high amounts of neurotoxin following phagocytosis of the pathogenic bacteria 
Clostridium difficile that were limited following the engulfment of Bifidobacterium bifidum. (C) 
In vitro interaction of human mast cells with Lactobacillus rhamnosus and SCFAs results in 
their modified functions and phenotypes with the implication of the KCa3.1 channel as well 
as Gpr41, 43 and 109a, respectively. (D) The differentiation of human monocytes into moDC 
in the presence of SCFAs induces modified secretory capacities compared to controls. (E) 
The efficacy of adoptive T cell therapy was proven to be associated with the microbiome. 
The success of adoptive T cell therapy correlates with a peripheral increase and a more 
abundant tumor infiltration of CD8α+DC producing IL-12 (1). Mouse treatment with SCFA 
results in the recruitment of bone marrow-derived DC with impaired capacity to induce Th2 
responses in the lung (2). Probiotics administered by gavage reduces the severity of allergic 
airway inflammation and AD through the reduction of eosinophil infiltration into the lung and 
skin, respectively (3). 
 
 
Figure 2. Microbiota engineering. The three main approaches to microbiota engineering 
are depicted: left, interventions to modify the microbiota species composition; right, 
engineering biosynthetic pathways for the production of compounds benefiting human health 
and homeostasis; bottom, engineering selected commensal strains for therapeutic protein 
live delivery. At the center of each circled approach a single bacterial cell is depicted as 
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commensal representative. These approaches have possible overlaps that allow better 
tailored design. All approaches can be envisaged to ameliorate or even prevent both allergy 
and cancer. 
 
Table 1. Definitions 
 
Term Definition 
Microbiota Microorganisms (bacteria, viruses, fungi, protozoa 
and archaea) populating the inner and outer 
surfaces of the human body 
Microbiome Collective genome of all microorganisms 
Mutualism A relationship between two organisms of different 
species resulting in benefits for both organisms from 
the interaction 
Symbionts Two different organisms of the same or of different 
species with a close and persistent biological 
interaction  
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Table 2. Prevalent bacteria at different sites under normal homeostasis 
 
 Phylum Class Order Family Species 
Skin Actinobacteria Actinobacteria Actinomycetales  Propionibacteriaceae Propionibacterium acnes  
 Firmicutes Bacilli Bacillales Staphylococcaceae Staphylococcus epidermis 
Gut       
upper 
part 
Firmicutes Bacilli Lactobacillales Streptococcaceae Streptococcus spp. 
    Lactobacillaceae Lactobacilli spp. 
distal 
part 
Firmicutes Clostridia Clostridiales Clostridaceae Clostridium spp 
 Actinobacteria Actinobacteria Bifidobacteriales Bifidobacteriaceae Bifidobacterium spp. 
 Bacteroidetes Bacteroidia Bacteriodales Bacteroidaceae Bacteroides spp. 
Lung Bacteroidetes Bacteroidia Bacteriodales Prevotellaceae Prevotella spp. 
 Firmicutes Bacilli Lactobacillales Streptococcaceae Streptococcus spp. 
 Proteobacteria Gammaproteoba
cteria 
Pasteurellales Pasteurellaceae Actinobacillus spp., etc. 
Nose Actinobacteria Actinobacteria Actinomycetales  Corynebacteriaceae Corynebacterium spp. 
 Firmicutes Bacilli Bacillales Staphylococcaceae Staphylococcus spp. 
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Table 3. Known modulators of the bacterial composition 
 
 Phylum Class Order Family Species 
Allergy 
rather increased Firmicutes Clostridia Clostridiales Clostridaceae Clostridium spp. 
    Ruminococcaceae Ruminococcus 
spp. 
rather decreased Bacteroidetes Bacteroidia Bacteriodales Bacteroidaceae Bacteroides 
spp. 
Diet 
ominivore Firmicutes Clostridia Clostridiales Lachnospiraceaeceae  
oligosacharrides Actinobacteria Actinobacteria Bifidobacteriales Bifidobacteriaceae Bifidobacterium 
spp. 
Western diet/fat Firmicutes Erysipelotrichia Erysipelotrichales  Erysiopelotrichaceae  
Vitamin D       
rather decrease Firmicutes Clostridia Clostridiales Lachnospiraceaeceae Coprococcus 
 Actinobacteria Actinobacteria Bifidobacteriales Bifidobacteriaceae Bifidobacterium 
spp. 
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Table 4. Diet and microbiota metabolites in allergy and cancer 
 
Compound Structure Effects in allergy and 
cancer 
Miscellaneous 
Iron Fe Poor iron associated with 
allergy and high serum iron 
increases risk of several 
cancers 
Folate  Serum folate is not 
correlated with allergic 
reactions, but with serum 
IgE. High plasma folate 
decreases risk of wheeze in 
children 
Vitamins 
Vitamin A  Retinol supplementation 
has no effect on allergy. Vit 
A increases Proteobacteria. 
Increased serum retinol is 
associated with prostate 
cancer. 
Vitamin D  Vitamin D supplementation 
reduces respiratory 
infections (not associated 
with allergy) and possibly 
reduces asthma incidence 
in offspring. Vitamin D 
reduces abundance of 
Bifidobacterium and 
Coprococcus and increases 
Proteobacteria. Vitamin D 
may prevent hematologic 
malignancies and advanced 
colorectal adenomas. 
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Non-digestible oligosaccharides 
Galacto-oligosaccharides 
 
Bacterial fermentation of 
NDO induces a shift from 
Bacteriodes and Prevotella 
species to beneficial  
Bifidobacterium and 
Lactobacillus species 
Specific NDO feeding 
reduced the development of 
AD in infants at risk of 
allergy, which was 
associated with increased 
Bifidobacterium and 
Lactobacilli. 
Specific NDO reduce 
allergic manifestations in 
experimental models for 
allergy  
Specific NDO influence 
microbiota diversity and 
prevent the progression of 
colorectal cancer. 
Fructo-oligosaccharides 
 
Agaro-oligosaccharides 
 
Short chain fatty acids 
Butyrate 
 
Butyrate and propionate 
inhibit HDAC activity and 
promote Treg cells.  Propionate 
 
Acetate 
 
Acetate does not inhibit 
HDAC. 
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